Drugs / NNC0113-5840
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07566390 | May → Nov 2026 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0113-5840 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07566390 ↗ |
| Route | Subcutaneous | “will be administered subcutaneously” NCT07566390 ↗ |